My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 91

    1.

    Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.

    Monami M, Lamanna C, Marchionni N, Mannucci E.

    Diabetes Care. 2008 Jul;31(7):1455-60. Epub 2008 Mar 28.PMID: 18375416 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

    Dahabreh IJ, Economopoulos K.

    Clin Trials. 2008;5(2):116-20. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added]. PMID: 18375649 [PubMed - indexed for MEDLINE]Related articles

    3.

    Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

    Singh S, Loke YK, Furberg CD.

    JAMA. 2007 Sep 12;298(10):1189-95.PMID: 17848653 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Rosiglitazone for type 2 diabetes mellitus.

    Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

    Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.PMID: 17636824 [PubMed - indexed for MEDLINE]Related articles

    5.

    Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.

    Diabetes Obes Metab. 2008 Dec;10(12):1221-38. Epub 2008 May 26. Review.PMID: 18505403 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

    Nissen SE, Wolski K.

    N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100.. PMID: 17517853 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE.

    JAMA. 2007 Sep 12;298(10):1180-8.PMID: 17848652 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

    Loke YK, Singh S, Furberg CD.

    CMAJ. 2009 Jan 6;180(1):32-9. Epub 2008 Dec 10.PMID: 19073651 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

    Lebovitz HE, Kreider M, Freed MI.

    Diabetes Care. 2002 May;25(5):815-21.PMID: 11978674 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.

    Monami M, Marchionni N, Mannucci E.

    Diabetes Res Clin Pract. 2008 Oct;82(1):48-57. Epub 2008 Sep 4.PMID: 18775581 [PubMed - indexed for MEDLINE]Related articles

    11.

    Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.

    Norris SL, Carson S, Roberts C.

    Curr Diabetes Rev. 2007 May;3(2):127-40.PMID: 18220664 [PubMed - indexed for MEDLINE]Related articles

    12.

    A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

    Chiquette E, Ramirez G, Defronzo R.

    Arch Intern Med. 2004 Oct 25;164(19):2097-104.PMID: 15505122 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Cardiovascular risk of rosiglitazone: another perspective.

    Waksman JC.

    J Pharm Pharmacol. 2008 Dec;60(12):1573-82. Review.PMID: 19000361 [PubMed - indexed for MEDLINE]Related articles

    14.

    Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

    Wagstaff AJ, Goa KL.

    Drugs. 2002;62(12):1805-37. Review.PMID: 12149047 [PubMed - indexed for MEDLINE]Related articles

    15.

    The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

    Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

    Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.PMID: 16860259 [PubMed - indexed for MEDLINE]Related articles

    16.

    A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.

    Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.

    Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):769-81.PMID: 18613278 [PubMed - indexed for MEDLINE]Related articles

    17.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    18.

    Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

    Lago RM, Singh PP, Nesto RW.

    Lancet. 2007 Sep 29;370(9593):1129-36. Review.PMID: 17905165 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    20.

    Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

    Pinelli NR, Cha R, Brown MB, Jaber LA.

    Ann Pharmacother. 2008 Nov;42(11):1541-51. Epub 2008 Oct 28.PMID: 18957626 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity